DNA testing market growth is anticipated to reach USD 10.04 billion by 2022

Rise in developments in the field of genome sequencing and personalized DNA level diagnostic applications, a considerable growth in the number of patented research initiatives by the government and government funded projects are factors expected to drive demand during the forecast period.

Introduction of novel technologies for genome profiling are expected to boost progress of this industry over the forecast period. Furthermore, increasing incidences of chronic oncology and infectious diseases that depend on DNA prototyping for treatment and diagnosis using personalized medicine are anticipated to significantly raise demand for DNA diagnostics/testing based research thereby propelling industrial growth in the coming years. Increasing demand for prenatal testing and in-vitro fertilization that subsequently leads to rise in demand for DNA diagnostics/testing is also attributive towards expected progress in this market.

View summary of this report, Click Here 

Further key findings from the study suggest:

• PCR based diagnosis accounted for the largest share of the market revenue in 2014 as a result of higher preference rate coupled with higher availability of products and reagent kits of this segment.
• Next generation sequencing application for DNA testing is estimated to witness significant progress with a double digit CAGR of over 16% amongst the other technology segments due to presence of significant advantages offered by this technique of DNA identification and testing.
• Infectious disease diagnostics accounted for the largest market share in 2014 due to higher incidence rate of various infectious disorders which subsequently raises the demand for in-vitro nucleic acid based diagnostic tests for diagnosis and monitoring of disease progression.
• There are diverse applications of DNA testing market out of which oncology diagnostics and histopathology is estimated to register lucrative growth over the forecast period. Factors attributing for considerable growth potential in this segment include identification of cancer causing genes & associated research, and facilitation in mutation detection
• North America dominated the market in 2014, with revenue estimated at over USD 2,600 million. Presence of sophisticated healthcare infrastructure, rising incidence of genetic abnormalities, favorable government initiatives with respect to genetic diagnosis and its application in in-vitro fertilization are major factors driving growth of this region.
• Asia Pacific is anticipated to witness lucrative growth as a result of developments in health care infrastructure in this region coupled with presence of significant number of target population that is suffering with chronic as well as acute disorders. Government initiatives taken up herein are also attributive to influence sector growth to a great extent.
• Key participants of DNA testing industry include Abbott Laboratories, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Applied Biosystems Group, Cepheid Inc., Transgenomic Inc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Alere Inc, Affymetrix Inc., Hologic, Dako, and 454 Life Sciences.

Click Here For Access Full Report : https://goo.gl/UKY4wm

Non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025

Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.

In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.

However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.

View summary of this report, Click Here 

Further Key Findings fromthe Report Suggest:

• The market is segmented on the basis of the tests carried out during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks
• 13-24 weeks accounted for the largest share owing to the presence of maximum number of the tests carried out in this phase of pregnancy
• High & average risk pregnancy held the larger share owing to presence of favorable payer reimbursement in this segment
• Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption
• Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies
• Some of the key players operating the market space include Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp
• One of the key trends followed by companies includes licensing of the test to other labs and generating significant revenue by collecting royalty payments

Click Here For Access Full Report : https://goo.gl/Y3Sd5N

Bone Morphogenetic Protein (BMP) Market Size Is Expected to Reach Over USD 644.6 Million By 2024

Increasing incidence of spinal fusion, trauma, and small bone surgeries coupled with demand for faster bone recovery are the key drivers affirming growth of BMP market.

Low back pain and spinal disc dislocation are some of the most common occupational hazards. Over 75% of such disorders require spinal surgery after noninvasive treatment options are unable to provide any relief. Minimally invasive surgery, shorter hospital stays, and fast recovery are common demands observed among patients. BMP has gained high acceptance among orthopedic surgeons in recent years owing to its ability to cater above mentioned benefits

Sport-related injuries, growing geriatric population, and increasing awareness about osteoinduction products as an alternative to bone grafting are other drivers accentuating market growth. BMP has reported outstanding results over bone graft, such as lack of donor morbidity, extensive surgical procedure, higher recovery time, pain & numbness, and high cost.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• rhBMP-2 and rhBMP-7 are the commercially available recombinant BMPs. rhBMP-2 is widely known for its high osteoinductive property for faster formation of bone and cartilage in bone fusion procedures
• rhBMP-2 held more than half of the market share in 2015. Key attributes contributing toward its growth are high acceptance, wide range of applications, and easier availability in developing countries
• rhBMP-7 on the other hand is expected to witness decline in market share over the forecast period owing to factors such as limited usage and discontinuation of OP-1from 2014 by Olympus
• Spinal fusion held the largest share in 2015. Increasing cases of sport-related spinal injuries, wide range of product availability, easier usage, and long-term reliability are major factors for the aforementioned dominance.
• North America held a significant share of over 65.0% in 2015. High number of orthopedic surgical procedures, and availability of favorable reimbursement policies are drivers that can be attributed to for largest share.

Click Here For Access Full Report : https://goo.gl/Rfbtos

Osteosynthesis devices market size is expected to reach a value of USD 9.9 billion by 2024

The worldwide prevalence of conditions like osteoporosis and osteomalacia, coupled with heavily occurring road traffic injuries/accidents and sporting injuries support the demand for osteosynthesis devices worldwide.

Osteoporosis, a disease resulting in weakening of bones is responsible for causing more than 8.9 million fractures annually. Forearm, humerus, hip and spine are the most commonly affected areas in patients suffering from the disease. The incidence and economic burden of osteoporosis is increasing worldwide, and patients 65 years old or over are at maximum risk of getting affected.

The geriatric population accounted for 46.2 million in 2014, and is increasingly rising. It is projected that by the year 2060, the number of older population will be twice than that of 2014. The rising incidence of osteoporosis and increasing count of the geriatric population is expected to drive demand for osteosynthesis devices in the coming years.

On the other hand, road traffic deaths are at the focal point of a crisis facing public health and development. The WHO reported that accidents/injuries majorly affect the low- and middle-income countries. Road accidents can cause severe injuries such as broken bones and fractures and requires immediate orthopediccare and attention. 

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• North America reported highest revenue growth in this market. U.S. is one of the most lucrative and commercially important markets for orthopedic device manufacturers. Furthermore, technical advancements and a growing aging population (14.5% of the U.S. population), coupled with increasing investments in healthcare sector is estimated to drive growth in the market.
• Asia Pacific is expected to be an attractive region for osteosynthesis devices. Asia Pacific is reported to be at a high risk for osteoporosis because of a reported rise in the elderly population.
• Internal fixation devices held a higher market share than external devices in 2015. Although complications such as infections, consolidation delays, and construct damage are causing concerns, this has indirectly led to the demand for new research and management options in the fight against osteoporosis and fractures.
• The development of absorbable and biocompatible internal bone fixation devices is responsible for leading the drive for constant innovation in the osteosynthesis devices market.
• Some of the key players in this industry include DePuy Synthes, Inc.; Smith & Nephew Plc; Stryker; Zimmer Biomet Holdings, Inc.; Globus Medical, Inc.; GS Medical, LLC; Life Spine, Inc.; MicroPort Orthopedics, Inc.; Néosteo SAS; and Precision Spine, Inc.

Click Here For Access Full Report :  https://goo.gl/BDRZNL

Follw us Linkedin : https://goo.gl/NCe1SW

Track and trace solutions market size is expected to reach USD 5.2 billion by 2025

The track and trace solutions market is anticipated to witness a high growth during the forecastperiod from 2016 to 2025. The high growth is attributed to a majority of factors, such as the increasing focus of pharmaceutical & biopharmaceutical companies on ensuring brand protection. The pharmaceuticals & medical devices manufacturers encounter a major threat from counterfeit products and theft. The deployment of track and trace solution helps manufacturers enhance distribution channel efficiency and reduces the frequency of counterfeit products.

Furthermore, rising adoption of track and trace solution by healthcare manufacturers would fuel the market growth in the long run. Introduction of advanced technology, such as RFID, provides fast reading and delivers high levels of security. However, the deployment cost of serialization & aggregation solutions, as well as lack of common regulations and standards,is expected to hamper market growth.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• The software solutions segment was the largest revenue-generating segment of the track and trace solutions market in 2015. This contribution ismainly because of the regulatory mandates for the execution of serialization & aggregation in healthcare sector
• The serialization solution was the largest grossing segment in 2015. Increasing application of serialization in pharmaceuticals & medical devices packaging will be a vital factor contributing to the sector growth
• The RFID segment is expected to exhibit fastest growth rate during the study period. The key factors attributing to the growth of the segment are technological advantages, such as high durability and reusability, more data storage capacity, and no requirement of line of sight
• North America is estimated to reign the global market in the year 2015. The rising implementation of regulatory standards & regulations along with high adoption rate of track and trace solutions by consumers is anticipated to contribute to the market growth
• Somekey players serving track and trace solutions market includeAxway; Mettler-Toledo International, Inc.; Optel Vision;Adents International; Antares Vision srl; TraceLink, Inc.;Siemens AG;ACG Worldwide,Seidenader Maschinenbau GmbH;and Systech, Inc. 

Click Here For Access Full Report : https://goo.gl/YPi0up

Prefilled Syringes Market Size Is Expected To Reach USD 22.5 Billion By 2025

Key factors driving the market expansion include technological advancements in auto-injectors and growing usage of prefilled syringes owing to its reduced prices per dose.

Prefilled injecting devices are rapidly replacing traditional syringe-vial combinations due to certain associated advantages such as increased patient safety and convenience offered to healthcare practitioners in dose preparation. Growing trend of self-injecting devices adopted for the management of chronic diseases, such as diabetes and rheumatoid arthritis, are expected to boost the growth of auto injectors and pen injectors during the forecast period. Growing prevalence of these diseases and introduction of advanced devices with Wi-Fi and Bluetooth connectivity that facilitate effective management of patient health records are factors expected to boost the usage of such devices.

Application of prefilled injectors is currently limited to emergency rooms in hospitals and for the treatment of certain chronic diseases. These injection devices are considered ideal containers for vaccines and biotech drugs, which otherwise tend to become unstable and react with the material of the container that result in altered drug potency. Growing preference toward biotechnology drugs and the emerging biotech space presenting greater opportunities are expected to have a positive impact on the growth of the prefilled syringes market during the forecast period. 

                                                   View summary of this report, Click Here 

Further key findings from the study suggest:

• The use of glass syringes to be high owing to their increasing preference amongst healthcare professionals; this is attributable to their ease of use and the low risk posed by these devices at the time of injection.
• However, the plastic segmentis rapidly replacing the former with the introduction of advanced plastic materials, such as polypropylene and crystal clear polymer, which are biocompatible as glass.
• Europe dominated the prefilled syringes space in 2015. High adoption of patient safety measures and presence of large number of market players are the factors responsible for the dominance of the region.
• North America region is expected to show the fastest growth rate during the forecast period due to rapid adoption of prefilled syringes in this region.
• The market is presently dominated by few key participants such as Gerresheimer AG, Haselmeier AG, Nipro Medical Corporation, Unilife Corporation,Owen Mumford, SCHOTT, Datwyler Pharma Packaging, and Becton, Dickinson and Company.
• The syringe manufacturing market is consolidated; however, various new players are bringing innovative technologies to this sphere,which can be used for the manufacturing of auto-injectors.

Click Here For Access Full Report : https://goo.gl/0kVMng

Microbiome therapeutics market worth is expected to reach USD 433.5 million by 2025

Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.

The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.

Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.

View summary of this report: Click Here 

Further Key Findings from the Study Suggest:

• Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome
• Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT
• No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.
• It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline
• C. difficile dominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period
• North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities
• Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China
• Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome
• High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players

Click Here  For Access Full Report : https://goo.gl/e2QCDE